In vivo cytokinetic effects of recombinant human growth hormone (rhGH) in patients with advanced breast carcinoma

E. Baldini, P. G. Giannessi, G. Gardin, A. Alama, F. Minuto, A. Barreca, P. F. Conte

Research output: Contribution to journalArticle

Abstract

We have investigated the possibility of inducing a kinetic recruitment of breast cancer cells by the in vivo administration of recombinant human Growth Hormone (rhGH). Twelve patients with advanced breast cancer received rhGH i.m. for 2 days immediately before the first course of chemotherapy. The following biological parameters have been evaluated before and 24 hours after rhGH administration: tumor TLI, tumor IGF-I content, serum IGF-I concentration. The mean tumor TLI values before and after rhGH were 1.3% and 2.6% respectively; median tumor and serum IGF-I levels before rhGH were 4.64 ng/g and 63.5 ng/ml respectively; after the administration of rhGH median tumor IGF-I content was 1.8 and median serum IGF-I level was 112 ng/ml. These data suggest that, in vivo, rhGH stimulates breast cancer cell proliferation; the mitogenic stimulus is likely due to the local production of IGF-I induced by rhGH.

Original languageEnglish
Pages (from-to)113-116
Number of pages4
JournalJournal of Biological Regulators and Homeostatic Agents
Volume8
Issue number4
Publication statusPublished - 1994

Keywords

  • Breast cancer cell proliferation
  • Growth hormone
  • IGF-I
  • Kinetic recruitment

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Endocrinology
  • Physiology
  • Immunology
  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Physiology (medical)

Fingerprint Dive into the research topics of 'In vivo cytokinetic effects of recombinant human growth hormone (rhGH) in patients with advanced breast carcinoma'. Together they form a unique fingerprint.

  • Cite this